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Abstract
Background: Proliferation and tumor differentiation captured by the genomic grade index (GGI) are important
prognostic indicators in breast cancer (BC) especially for the estrogen receptor positive (ER+) disease. The aims
of this study were to convert this microarray index to a qRT-PCR assay (PCR-GGI), which could be realized on
formalin fixed paraffin embedded samples (FFPE), and to assess its prognostic performance and predictive value
of clinical benefit in early and advanced ER+ BC patients treated with tamoxifen.
Methods: The accuracy and concordance of the PCR-GGI with the GGI was assessed using BC patients for which
frozen and FFPE tissues as well as microarray data were available (n = 19). The evaluation of the prognostic value
of the PCR-GGI was assessed on FFPE material using a consecutive series of 212 systemically treated early BC
patients. The predictive performance for tamoxifen benefit was assessed using two ER+ BC populations treated
either with adjuvant tamoxifen only (n = 77+139) or first-line tamoxifen for advanced disease (n = 270).
Results: The PCR-GGI is based on the expression of 8 genes (4 representative of the GGI and 4 reference
genes). A significant correlation was observed between the microarray-derived GGI and the qRT-PCR assay using
frozen (ρ = 0.95, p < 10E-06) and FFPE material (ρ = 0.89, p < 10E-06). The prognostic performance of the PCR-
GGI was confirmed on FFPE samples (HRunivar. = 1.89; [95CI:1.01-3.54], p = 0.05). The PCR-GGI further identified
two subgroups of patients with statistically different time to distant metastasis free survival (DMFS) across the
two cohorts of ER+ BC patients treated with adjuvant tamoxifen. Additionally, the PCR-GGI was associated with
response to tamoxifen in the advanced setting (HRunivar. = 1.98; [95CI:1.51-2.59], p = 6.9E-07).
Conclusion: PCR-GGI recapitulates in an accurate and reproducible manner the performances of the GGI using
frozen and FFPE samples.
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Background
Gene expression profiling has resulted in paradigm shift
in the way that researchers and clinical investigators view
breast cancer (BC) biology. During the last years, several
groups have evaluated the potential of gene expression
profiles to improve BC prognostication. This has resulted
in the identification of several gene signatures, most of
them outperforming current clinico-pathological parame-
ters in predicting clinical outcome (reviewed in [1]).
One example is the genomic grade index (GGI) developed
by our group [2]. The hypothesis beyond the develop-
ment of this index was to improve BC grading and its
prognostic value. This index includes 97 genes that are
consistently differentially expressed between low and
high histological grade breast tumors. Of interest, the
majority of them are related to cell cycle and proliferation.
One of the major findings of that study was that GGI
could assign intermediate histological grade tumors into
two distinct subgroups whose gene expression profiles
and clinical outcome was similar to the ones of low and
high histological grade tumors respectively. In addition,
GGI could identify two clinically relevant ER+ subtypes
with very distinct clinical outcomes in both systemically
untreated and tamoxifen only treated BC patients [3].
Finally, comparative studies of the GGI with other prog-
nostic gene signatures in the context of a large meta-anal-
ysis involving ~3000 BC patients suggest that most of
these signatures have a similar prognostic performance
which is limited to the ER+ disease, and that the prolifer-
ation and cell-cycle genes represent the driving force of
these signatures [4,5].
In this study we aimed to transpose the GGI onto a qRT-
PCR assay based on a minimal set of genes that could reca-
pitulate in an accurate and reproducible manner the prog-
nostic performance of GGI using both frozen and
paraffin-embedded (FFPE) tumor samples, to facilitate its
use in clinical practice. Furthermore, we investigated the
performance of this assay to predict benefit to adjuvant
tamoxifen in early BC patients or to first line tamoxifen in
advanced BC patients.
Results
Development of the reduced genomic qRT-PCR grade 
index (PCR-GGI)
The first step in the development of the PCR-GGI was to
identify a minimum number of genes that could recapitu-
late the performance of the original GGI.
To this end, we first tested the correlation of the expres-
sion values of several random combinations of minimum
4 genes, covering all phases of the cell cycle, with the orig-
inal GGI. This correlation was performed using gene
expression data from two publicly available microarray
data sets namely the NKI [6] and VDX [7]. We selected a
set of four genes (MYBL2, KPNA2, CDC2 and CDC20)
based on their high significant correlation with the origi-
nal GGI (0.95 and 0.94 (all P < 10-6) in the NKI and VDX
data sets respectively). We also selected 4 reference genes
(GUS, TBP, RPLPO and TFRC). Although all housekeep-
ing genes gave similar results for normalizing the data, the
variance of the estimation of the housekeeping Ct value
was reduced by using the mean of these 4 reference genes
(data not shown).
The prognostic performance of this reduced gene set
(GGIreduced) was then compared to the performance of
the original GGI in the NKI and VDX data sets. This com-
parison revealed similar prognostic performances (NKI
data set: HRGGI = 1.73; [95%CI: 1.40-2.14], p = 4.2E-07
and HRGGIreduced = 1.49; [95%CI: 1.21-1.82], p = 1.2E-04;
VDX data set: HRGGI = 1.41; [95%CI: 1.13-1.76], p = 2.0E-
03 and HRGGreduced = 1.36; [95%CI:1.09-1.68], p = 5.8E-
03). Of interest, the correlation values with the original
GGI and the prognostic performances were not improved
when additional genes were taken into consideration
(data not shown).
The second step in developing the PCR-GGI was to con-
vert these four genes into a qRT-PCR index. To this end,
we designed primers for the four selected genes as well as
for four reference genes considering the SYBR-based real-
time PCR assay platform. We assessed the concordance
between the microarray-derived GGI and the PCR-GGI
measured on frozen and FFPE tissues using a series of 19
primary BC from which frozen, FFPE tissues and their cor-
responding microarray data were available, further
referred as "IJBtest". A statistically significant correlation
was observed between the expression levels of the micro-
array-derived GGI and the PCR-GGI assay using frozen
samples (ρ = 0.95 [95%CI: 0.86-0.98], p = 3.6E-09) as
well as FFPE samples (ρ = 0.89 [95%CI: 0.72-0.96], p =
8.26E-07) (see Table 1). Similarly, a statistically signifi-
cant correlation was found between the expression levels
of the PCR-GGI derived from frozen and FFPE samples
respectively (ρ = 0.85 [95%CI: 0.64-0.94], p = 7.7E-06).
Interestingly, the correlations between the microarray-
derived GGI and the PCR-GGI assay on frozen and FFPE
samples were higher when the 4 genes were combined
together compared to the individual genes (see table 1).
Prognostic performance of the PCR-GGI
To evaluate the prognostic performance of the PCR-GGI,
we considered an independent population of 212 primary
BC FFPE samples originated from patients consecutively
diagnosed at the Jules Bordet Institute between 1995 andBMC Genomics 2009, 10:424 http://www.biomedcentral.com/1471-2164/10/424
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1996 (referred as IJB95/96). The clinico-pathological
characteristics are summarized in Table 2.
The prognostic performances of the individual four genes
(included in the PCR-GGI) were compared to the one of
the PCR-GGI and summarized in Table 3. The group of
patients with high PCR-GGI scores was associated with a
higher risk of recurrence than the group of patients with
low PCR-GGI (HR = 1.89; [95%CI: 1.01-3.54], p = 0.05;
see Figure 1a). However, this association was not signifi-
cant but showed a trend towards significance in the mul-
tivariate analysis. Indeed, when selecting the age of the
patient, the size of the tumor, the centrally reviewed his-
tological grade, the nodal status and the PCR-GGI as vari-
ables for the multivariate analysis using a backward
stepwise selection for the identification of the covariates
to be kept in the final Cox regression model for distant
metastasis free survival (DMFS), only the nodal status
(HR = 3.10; [95%CI: 1.53-6.27], p = 0.002) and PCR-GGI
(HR = 1.89; [95%CI: 0.94-3.77], p = 0.07) were still
present in the last step of the analysis.
As expected, histological grade 2 tumors (n = 89) spanned
the expression levels of PCR-GGI of histological grade 1
and 3 (data not shown). Similarly to GGI, PCR-GGI
divided histological grade 2 tumors into two subgroups
with distinct clinical outcome although of borderline sig-
nificance (HR = 2.27; [95%CI: 0.94-5.49], p = 0.07; see
Figure 1b).
Since we previously demonstrated that the GGI was par-
ticularly performant at identifying high and low risk
patients within the ER-positive population [3], we
restricted our analysis to the ER+ subpopulation of the
"IJB95/96" cohort. In order to identify these ER-positive
patients, we evaluated ER by qRT-PCR and defined a cut-
off for positivity based on the binomial repartition of ER
score (see Material and methods). Sixty-four percent
(136/212) of the samples were considered as ER-positive.
Overall concordance with IHC data assessed on 162 FFPE
samples (76%) for which both IHC and qRT-PCR results
were available was of 75% with a correlation of 0.38 (p =
9E-07). When PCR-GGI was applied to these ER+ sam-
ples, Kaplan-Meier survival curves and Cox analyses
revealed a significant association between a high risk of
recurrence and a high PCR-GGI score (HR = 2.26; [95%CI:
1.08-4.75], p = 0.03; see Figure 1c).
Several studies have demonstrated that the widely used
proliferation marker Ki-67 evaluated by IHC predicts clin-
ical outcome [8]. We therefore evaluated the prognostic
value of Ki-67 by IHC in the IJB95/96 series (N = 160).
There was no significant association between Ki-67 and
the risk of recurrence both when considering Ki-67 as a
continuous variable (HR = 1.01; [95%CI: 0.99-1.03], p =
0.19) or as a binary variable using the cut-off of
>15%;(HR = 1.03; [95%CI: 0.51-2.07], p = 0.93).
Assessment of the performance of the PCR-GGI in 
tamoxifen-treated BC patients
In order to assess a potential predictive value of the PCR-
GGI for clinical benefit to tamoxifen, we evaluated its per-
formance in three independent ER-positive BC popula-
tions treated either with adjuvant tamoxifen only or with
first-line tamoxifen for advanced disease.
i) ER-positive BC patients treated with adjuvant tamoxifen only
The potential value of the PCR-GGI to predict DMFS in
tamoxifen-treated patients was first evaluated in a
patient's series on which the original GGI was previously
computed [3] (n = 77), offering the possibility to compare
the performance of GGI and PCR-GGI (referred as OXFD,
see Table 2). Of note, 62% (45/73) of the samples origi-
nated from node-negative patients.
We observed a significant association between a high
PCR-GGI score and a higher risk of recurrence (HR = 3.34;
[95%CI: 1.19-9.37], p = 0.01). This performance
appeared similar to the one of the original GGI (HRunivar.
= 4.89; [95%CI: 1.73-13.83]; p = 0.003) and superior to
the one of the histological grade (HRunivar. = 2.01; 95%CI:
[0.87-4.67]; p = 0.10). The Kaplan-Meier curves for the
histological grade, the PCR-GGI and the original GGI are
illustrated in Figure 2. When selecting the age of the
patient, the size of the tumor, the histological grade, the
nodal status and the PCR-GGI as variables for the multi-
variate analysis using a backward stepwise selection for
the identification of the covariates to be kept in the final
Table 1: Correlation between the original GGI index and the qRT-PCR index derived from frozen and FFPE samples.
genes GGI vs GG qRT-PCR
(Frozen)
GGI vs GG qRT-PCR
(FFPE)
GG qRT-PCR
Frozen vs FFPE
Cor.coef CI95% p.val. Cor.coef CI95% p.val. Cor.coef CI95% p.val.
CDC20 0.933 [0.825-0.975] 1.70E-08 0.732 [0.403-0.893] 5.55E-04 0.775 [0.482-0.912] 1.60E-04
CDC2 0.644 [0.253-0.854] 3.93E-03 0.819 [0.57-0.93] 3.22E-05 0.694 [0.336-0.877] 1.39E-03
MYBL2 0.772 [0.478-0.911] 1.73E-04 0.589 [0.168-0.828] 4.92E-05 0.831 [0.596-0.935] 1.91E-05
KPNA2 0.762 [0.458-0.906] 2.37E-04 0.64 [0.247-0.852] 4.22E-03 0.73 [0.4-0.893] 5.78E-04
4 genes 0.95 [0.86-0.98] 3.6E-09 0.89 [0.72-0.96] 8.26E-07 0.85 [0.64-0.94] 7.7E-06BMC Genomics 2009, 10:424 http://www.biomedcentral.com/1471-2164/10/424
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Table 2: Population characteristics
OXFD IJB95/96 JNIadj JNImeta
(n = 77) (n = 212) (n = 139) (n = 270)
Mean age at diagnosis
(years) 6 45 8 . 56 45 8
(range) (40-86) (31-87) (46-87) (26-89)
Menopausal status
Premenopausal /5 47 9 5
Postmenopausal / 135 132 175
UK* 77 23 0 0
Event free survival DMFS/ DMFS/ RFS/ Progression/
(mean; months) 67 78.7 46 13.4
(range) (0.26-129) (0.13-142.27) (2-129) (1-70)
Death
Yes /2 4 5 1 1 7 9
No / 188 88 91
Tumor size
≤2 31 95 25 /
>2 46 95 81
(mean) 3.14 2.29 2.6
(range) (1-7) (0.15-8) (1-8)
UK* 22 33
Histological grade
1 13 (16.7%) 37 (17.5%) 1 (0.01%) 1 (0.003%)
2 40 (51.2%) 89 (42.5%) 16 (11.5%) 34 (12.6%)
3 13 (16.7%) 83 (39.2%) 77 (55.4%) 154 (57.0%)
UK* 11 (15.4%) 3 (0.01%) 45 (32.3%) 81 (30.0%)
Number of metastasis sites
0 50 171 / /
1 24 20
2 31 9
≥ 3 02
Histo. Estrogen Receptor status (>10% or ≥10 fmol/mg$)
Positive 77 114 139$ 270$
Negative 06 20 $ 0$
UK* 03 60 $ 0$
Histo. Progesterone Receptor status (>10% or = 10 fmol/mg)
Positive /8 2 8 8 $ 216$
Negative 90 43$ 46$
UK* 40 8$ 8$
Histo. Ki-67 status (>15%)
Positive /6 4//
Negative 98
UK* 50
No Positive Lymph Nodes (at surgery)
0 45 115 0 121
1 - 3 28 49 96 117
≥ 4 03 6 4 3 2 8
UK* 41 204
*:UK = Unknown.BMC Genomics 2009, 10:424 http://www.biomedcentral.com/1471-2164/10/424
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Cox regression model for DMFS, only the tumor size (HR
= 6.22; [95%CI: 1.35-28.75], p = 0.02), the age of the
patient (HR = 0.27; [95%CI: 0.07-1.03], p = 0.06), and
PCR-GGI (HR = 2.53; [95%CI: 0.80-7.99], p = 0.12) were
still present in the last step of the analysis.
The PCR-GGI was further applied to an independent pop-
ulation of 139 ER-positive BC samples originated from
node positive patients that received adjuvant tamoxifen
for primary disease (referred as JNIadj; see Table 2). Again,
we observed a statistically significant association between
a high PCR-GGI score and a higher risk of recurrence (HR
= 1.87; [95%CI: 1.13-3.09], p = 0.015). The Kaplan-Meier
curves are illustrated in Figure 3. Interestingly, a 3-years
delay of recurrence was observed between the patients
with low and high PCR-GGI.
The PCR-GGI remained significantly associated with
DMFS in the multivariate analysis (HR = 1.97; [95%CI:
1.09-3.55], p = 0.024) together with tumor size (HR =
2.65; [95%CI: 1.25-5.61], p = 0.011), but not with the age
of the patient. Of note, the nodal status and the histolog-
ical grade were not included in the analysis due to the
node-positivity of all patients and the high number of
missing values for the histological grade.
ii) ER+ BC patients treated with first-line tamoxifen for metastatic 
disease (JNImeta)
The PCR-GGI was applied to an independent population
of 270 ER+ BC samples originated from patients that
received first-line tamoxifen for advanced disease
(referred as JNImeta; see Table 2).
A statistically significant association was observed
between a high PCR-GGI score and progression-free sur-
vival (PFS) (HR = 1.98; [95CI: 1.51-2.59], p = 6.9E-07);
disease progression after start of first-line tamoxifen being
observed with a delay of 7.5 months in the patients with
low PCR-GGI compared to the patients with high PCR-
GGI at 50% PFS (see Figure 4). The PCR-GGI remained
significantly associated with PFS in the multivariate anal-
ysis (HR = 1.98; [95CI: 1.51-2.59], p = 6.9E-07). We also
observed a significant association between the PCR-GGI
and response to tamoxifen as the patients with a low PCR-
GGI score had a higher probability of response to
tamoxifen (74.5% versus 53% for the patients with high
PCR-GGI scores, p = 5E-04). The PCR-GGI correctly clas-
sified 81 of the 106 non-responders patients in the high
grade subgroup of samples (76.5% sensitivity, 95%CI: 67-
84%) and 73 of the 164 patients with objective response
(OR) or stable disease lasting over six months in the low
grade subgroup of samples (44.5% specificity, 95%CI: 37-
52%) with an odds ratio of 2.59 (95%CI: 1.51-4.48).
Discussion
In this study, we have developed a qRT-PCR grade index
(PCR-GGI) composed of four genes associated with cell
cycle progression and proliferation initially included in
the GGI [2]. This gene set includes MYBL2, KPNA2, CDC2
and CDC20, which together cover all phases of the cell
cycle. Indeed, MYBL2 encodes a nuclear protein involved
in cell cycle progression; KPNA2 is involved in the import
of proteins to the nuclear envelope and acts as a regulator
of cell cycle checkpoint mediators; CDC2 encodes a cata-
lytic subunit of the highly conserved protein kinase com-
plex known as M-phase promoting factor (MPF) which is
essential for G1/S and G2/M phase transitions; and,
CDC20 encodes a protein acting as a regulatory protein
interacting with several other proteins at multiple points
in the cell cycle.
We demonstrated that a quantitative assessment of a very
small number of genes is sufficient to recapitulate the per-
formance of the original GGI, especially in ER-positive
breast cancer. This could be explained by the fact that the
expression levels of most genes of the GGI signature are
highly correlated with one another. Two out of the four
genes included in our PCR-GGI signature were also
present in a number of previously reported prognostic sig-
natures; MYBL2 was part of the Recurrence Score devel-
oped by Paik et al. [9] as well as the microarray signatures
defined by Naderi et al. [10] and Miller et al. [11], whereas
the KPNA2 gene was present in the 76-gene signature of
Wang et al. [7], which has been applied successfully on a
cohort of node-negative estrogen receptor positive breast
cancer patients to predict benefit of tamoxifen [12].
We further showed that the averaged expression of the
four selected genes evaluated by qRT-PCR using FFPE
samples accurately recapitulates the prognostic perform-
ance of the GGI. Moreover the PCR-GGI was conducted
with success from 10 years old FFPE samples. Fourteen
percent of the samples have been excluded from the study
and this number is expected to be lower using recent FFPE
samples.
Additionally, as illustrated in this manuscript, the PCR-
GGI has several advantages which highlight its clinical rel-
evance.
Table 3: Prognostic performance of the individual 4 genes 
included in the PCR-GGI
HR CI (95%) P.val
HR CI (95%) P.val
CDC20 1.14 0.98-1.14 0.096
MYBL2 1.07 0.94-1.22 0.304
KPNA2 1.12 1.04-1.21 0.004
PCR-GGI 1.89 1.01-3.54 0.05BMC Genomics 2009, 10:424 http://www.biomedcentral.com/1471-2164/10/424
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First, as illustrated previously for the GGI, the PCR-GGI is
able to identify high and low-risk patients within the sub-
group of patients with intermediate histological grade
tumors, possibly improving treatment decision making
for these patients.
Second, as the GGI, the PCR-GGI is able to identify a
higher proportion of early breast cancer patients at low
risk of recurrence than do the clinical guidelines. This
means that the number of patients that would receive
unnecessary treatment could be reduced by applying this
molecular assay.
Third, the PCR-GGI is not subject to reproducibility and
inter-observer variability problems such as the histologi-
cal grading. Moreover, the PCR-GGI's procedure devel-
oped at Jules Bordet was easily transferred at the Josephine
Nefkens Institute, Rotterdam following some inter-labo-
ratory tests which gave great confidence in the reproduci-
bility of the assessment of the PCR-GGI. Also, the PCR-
GGI cut-off for positivity identified at the Jules Bordet
IJB95/96 FFPE Population Figure 1
IJB95/96 FFPE Population: Distant metastasis free survival analysis for the IJB95/96 FFPE population by qRT-PCR grading. 
(A) Analysis of the whole population: PCR-GGI low = blue and PCR-GGI high = red (B) Analysis of the histological grade 2 
(HG2) tumors by qRT-PCR grading. The 89 patients with HG2 tumors were separated into low-and high-risk subsets by this 
signature as PCR-GGI low = blue and PCR-GGI high = red. (C) Analysis of the ER+ samples: PCR-GGI low = blue and PCR-
GGI high = red. Difference in relapse-free survival between two groups is summarized by the hazard ratio (HR) for recurrence 
with its 95% CI. All statistical tests were two-sided.
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OXFD Population Figure 2
OXFD Population: Distant metastasis free survival analysis for the Oxford (OXFD) ER+ frozen population. (A) Analysis of 
the whole population by histological grade (HG1 (blue), HG2 (gray) and HG3 (red)). (B) Analysis of the whole population by 
gene expression grade index (GGI) (GGI low = blue and GGI high = red). (C) Analysis of the whole population by qRT-PCR 
grading: PCR-GGI low = blue and PCR-GGI high = red. Difference in relapse-free survival between two groups is summarized 
by the hazard ration (HR) for recurrence with its 95% CI. All statistical tests were two-sided.
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Institute was easily applied on the Josephine Nefkens
Institute assays.
Fourth, the PCR-GGI can classify ER-positive BC patients
treated either with adjuvant tamoxifen only or first-line
tamoxifen for advanced disease into clinically relevant
subgroups. We first observed a statistically significant
association between a high PCR-GGI score and a higher
risk of recurrence in ER-positive BC samples from patients
that received adjuvant tamoxifen for primary disease
across two different BC populations. We also observed a
statistically significant association between a high PCR-
GGI score and a higher risk of progression in ER+ BC sam-
ples originated from patients that received first-line
tamoxifen for advanced disease. However, the determina-
tion of ER positivity might also play a role in the assess-
ment of the performance of the PCR-GGI since we report
here a discordance of 25% between IHC and RT-PCR
assessment of ER.
Finally, the PCR-GGI has two practical advantages: 1/ it
requires only very small amounts of routinely available
FFPE samples, whereas the original GGI requires fresh-fro-
zen material, and 2/ it allows the use of a SYBR-based
technology, instead of the specific Taqman probes
(Applied Biosystems), providing the advantages of being
easy to use and cheaper than specific probes. Therefore,
we might envisage that this test could be carried out in
local certified pathology laboratories.
Additionally, several studies have demonstrated that
tumors with characteristics associated with poor histolog-
ical grade and high proliferating index tended to respond
better to chemotherapy [13,14]. As our signature was
derived from the histological grade we might then
hypothesize that the PCR-GGI not only quantifies the
likelihood of BC recurrence in women with node-negative
ER+ BC, it might also predict the magnitude of chemo-
therapy benefit.
Conclusion
As for the GGI, the clinical potential of the PCR-GGI is
obvious since: 1/ the three category of histological grading
is replaced by a two-category grading clinically more rele-
vant, 2/ it classifies ER-positive BC patients into two clin-
ically relevant subgroups, and 3/ the genes expression
JNIadj Population Figure 3
JNIadj Population: Relapse free survival analysis for JNIadj ER+ node positive tamoxifen only treated population by qRT-PCR 
grading: PCR-GGI low = blue and PCR-GGI high = red. The low-risk patients recurring 3 years later compared to high-risk 
patients (difference observed at 50% survival). Difference in relapse-free survival between two groups is summarized by the 
hazard ratio (HR) for recurrence with its 95% CI. All statistical tests were two-sided.BMC Genomics 2009, 10:424 http://www.biomedcentral.com/1471-2164/10/424
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score is not subject to inter-observer variability as is the
histological grade. Additionally, the PCR-GGI presents the
advantage that it can be evaluated on FFPE samples,
which are more widely available than frozen samples.
Methods
Patients and Samples Collection
A small series of 19 primary BC from which frozen, FFPE
tissues and their corresponding microarray data were
available, further referred as "IJBtest", was used to com-
pare the accuracy and the concordance of the microarray-
derived GGI to the qRT-PCR genomic grade index (PCR-
GGI).
The prognostic value of the PCR-GGI was evaluated in a
consecutive series of 212 FFPE primary BC samples col-
lected at the Jules Bordet Institute from 1995 to 1996,
referred as "IJB95/96". Median follow-up was of 7 years.
The clinical value of the PCR-GGI for tamoxifen benefit
was evaluated in three independent BC populations
derived from two independent institutions:
1) A series of 77 frozen ER+, node-negative and -positive
adjuvant tamoxifen-only treated primary BC collected at
the John Radcliff Hospital (Oxford, UK) for which micro-
array data were available, referred as "OXFD". Median fol-
low-up was of 5 years.
2) A series of 139 frozen ER+, node positive, adjuvant
tamoxifen only treated primary BC collected from 1979 to
2001 at the Josephine Nefkens Institute of the Erasmus
MC Rotterdam (NL), referred as "JNIadj". Median follow-
up was of 3.5 years.
3) A series of 270 frozen ER+ BC samples from hormone-
naïve patients that received first-line tamoxifen for meta-
static disease [of which 52 patients received adjuvant
chemotherapy], collected from 1979 to 2001 at the Jose-
phine Nefkens Institute of the Erasmus MC Rotterdam,
(NL), referred as "JNImeta". Median follow-up was of 5
years.
All frozen as well as FFPE samples contained >30% of
invasive tumor cells. This study was approved by the eth-
JNImeta Population Figure 4
JNImeta Population: Progression free survival (PFS) analyses for JNImeta ER+ advanced BC tamoxifen only treated patients 
by qRT-PCR grading: PCR-GGI low = blue and PCR-GGI high = red. The low-risk patients recurring 7.5 months later com-
pared to high-risk patients (difference observed at 50% survival). Difference in progression-free survival between two groups is 
summarized by the hazard ratio (HR) for recurrence with its 95% CI. All statistical tests were two-sided.BMC Genomics 2009, 10:424 http://www.biomedcentral.com/1471-2164/10/424
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ics committee of the Institut Jules Bordet, the John Rad-
cliffe Hospital and the Josephine Nefkens Institute of the
Erasmus MC Rotterdam (MEC 02.953). The JNIadj and
JNImeta samples involved coded tumor tissues and execu-
tion of this part of the study was performed in accordance
with the Code of Conduct of the Federation of Medical
Scientific Societies in the Netherlands http://
www.fmwv.nl/.
RNA extraction and purification
RNA from frozen samples was extracted for the OXFD and
IJBtest cohorts from four 10-μm sections using Trizol rea-
gent according to the supplier's instructions (Invitrogen
Life Technologies, Carlsbad, CA). For the JNIadj and
JNImeta cohorts RNA was extracted from 30-μm sections
using RNABee (Campro Scientific) as previously
described [15].
RNA from FFPE samples was extracted from three 10-μm
sections using the MasterPure Purification kit (Epicentre,
Madison, WI) after paraffin removal with xylene. A DNase
I treatment step was included.
To evaluate RNA quality and concentration, RNA from
frozen samples were loaded onto an Agilent RNA 6000
NanoLabChip (RNA LabChip, Agilent Technology, Santa
Clara, CA) in combination with the Bioanalyser 2100.
Samples with a total area under the 28S and 18S bands of
less than 15% of the total RNA band area, as well as a 28S/
18S ratio of less than 1.1, were considered to be degraded.
The RNA concentration from FFPE samples was analyzed
with the NanoDrop® ND-1000 UV-Vis Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA).
cDNA synthesis
For the "OXFD" and "IJB95/96" cohorts reverse transcrip-
tion (RT) was performed using a Super-Script First-Strand
Synthesis kit for RT-PCR (Invitrogen Corp., Carlsbad, CA).
Total RNA (300 ng) was reverse transcribed in a final vol-
ume of 21 μl with 50 ng of random hexamers. For the
"JNIadj" and "JNImeta" cohorts cDNA was synthesized
from 2 μg total RNA using random hexamers and oligo
dTs, as previously described [15]. A RNase H treatment
step was included in all protocols.
PCR amplification
Quantitative PCR (qPCR) reactions were performed in 96-
well plates using Applied Biosystems Prism 7900 HT
(TaqMan instruments) and a Stratagene Mx3000P QPCR
System (Agilent Technologies, Waldbronn, Germany).
Gene expressions were measured in duplicate using 5 ng
equivalent cDNA per reaction well. Amplifications were
performed in 25 μl PCR mixture containing 300-600 nM
of each primer and 12,5 μl 2× SYBR Green PCR Master
Mix (Applied Biosystems). After 2 min at 50°C and 10
min at 95°C, cDNA was subjected to 40 cycles of PCR
with a denaturation step at 95°C for 30 sec followed by a
combined annealing/extension step at 60°C for 1 min.
Primers of the selected genes were designed using the
Primer Express software (PE Applied Biosystems-see Table
4 for primer sequences).
Four housekeeping genes were selected on the basis of the
literature as reference genes for data normalization: TFRC,
GUS, RPLPO and TBP [16]. All PCR assays were run in
duplicate. For all our samples the average value for the
housekeeping gene is highly similar therefore all samples
with no expression or a lower Ct value of the housekeep-
ing genes compared to the value of the global population
were excluded from the analyses. Six percent of frozen and
14% of FFPE samples were then excluded from the analy-
ses.
PCR-GGI assay was developed at the Jules Bordet Institute
on Jules Bordet populations and validated both at the
Jules Bordet (IJB95/96, OXFD) and the Josephine Nefkens
Institutes (JNIadj, JNImeta) on independent populations.
Data analysis
qRT-PCR data normalization and PCR-GGI computation
The average of the housekeeper genes values was used as
reference and a Ct value of GGI genes was defined for each
sample by taking off this average. To calculate the reduced
gene expression grade index, we averaged the normalized
values of the four GGI genes. This is illustrated by the fol-
lowing formula:
where sj is the PCR-GGI score for patient j, Gi is the raw
gene expression of the ith gene in the PCR-GGI signature
for patient j, and   is the mean of the housekeeping
genes used for normalization.
In order to classify patients into low- and high-risk
groups, a cut-off was defined as the middle point between
the averages of the values of histological grade 1 and his-
tological grade 3 tumors. This cut-off was defined on fro-
zen samples (OXFD). To correct for the difference in scale
of PCR-GGI scores between frozen and FFPE samples, we
transformed the qRT-PCR scores derived from FFPE ER-
positive patients such that the mean and standard devia-
tion were equal to those from frozen samples:
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where sj is the PCR-GGI score for patient j from a FFPE
sample,  μf and  μp are the mean value of the PCR-GGI
scores for ER-positive frozen and FFPE tumor samples
respectively, and σf and σp are the standard deviation of
the PCR-GGI scores of ER-positive frozen and FFPE tumor
samples respectively.
Evaluation of estrogen receptor (ER) and Ki-67 expression 
by immunohistochemistry (IHC)
Paraffin-embedded blocks routinely fixed in neutral buff-
ered formalin were cut on poly-L-Lysine-coated slides and
stained with antibodies to ER clone 6F11 (dilution 1/40,
Novocastra, Newcastle, UK) and to Ki-67 clone MIB-1
(dilution 1/50; DAKO, Carpinteria, CA). Antigen retrieval
was performed in citrate buffer pH6 as previously
described [17]. The Ventana Nexes automated immunos-
tainer (Ventana Medical Systems, Tucson, Az) was used
with standard reagents. Tumors were defined as ER nega-
tive if < 10% of tumor cells had positive immunostaining
and as highly proliferating samples if >15% of tumors
cells had positive Ki-67 immunostaining.
ER evaluation by qRT-PCR
In order to consistently identify the ER status of BC
patients, we clustered the tumors using the ESR1 qRT-PCR
expressions by fitting Gaussian mixture models [18] with
equal and diagonal variance for all clusters. We used the
Bayesian Information Criterion [19] to test the number of
components. Each tumor was then automatically classi-
fied as ER-positive or ER-negative using the maximum
posterior probability of membership to these two clusters.
Survival analysis
We considered DMFS of BC patients as endpoint for the
"IJB95/96" and "JNIadj" data sets and PFS as endpoint for
the "JNImeta" data set. Criteria for follow up, type of
response and response to therapy were defined by stand-
ard International Union Against Cancer criteria of tumor
response [20]. PFS results were described previously [21].
Table 4: Forward and reverse primers sequences for signature and normalization genes.
Gene Name Accession number Primer sequence
4-genes signature
myb myeloblastosis viral oncogene homolog (avian)-like 2 (MYBL2) NM_002466 -AGCAAGTGCAAGGTCAAATGG
-CTGTCCAAACTGCCTCACCA
karyopherin alpha 2 (KPNA2) NM_002266 -TAAGGCAGATTTTAAGACACAAAAGG
-GTTCAACTGTTCCACCACTGGTATA
cell division cycle 2 (CDC2) NM_001786 -GCCGCCGCGGAATAAT
-CCTTCTCCAATTTTCTCTATTTTGGT
cell division cycle 20 homolog (CDC20) NM_001255 -CTTCCCTGCCAGACCGTATC
-CCAATCCACAAGGTTCAGGTAATA
Genes of Normalization
glucuronidase beta (GUS) NM_000181 -GAGTGGTGCTGAGGATTGGC
-TCTAGCGTGTCGACCCCATT
TATA box binding protein (TBP) NM_003194 -GCCCGAAACGCCGAATAT
-TCGTGGCTCTCTTATCCTCATGA
ribosomal protein, large, P0 (RPLP0) NM_001002 -ACCAAGGAGGACCTCACTGAG
-ACCAGCACGGGCAGCAG
transferrin receptor (TFRC) NM_003234 -GGAGCCAGGAGAGGACTTCC
-TTCTCCGACAACTTTCTCTTCAGG
ER
estrogen receptor 1 (ESR1) NM_000125 -TGTTCCAAACCCATCGTCAGT
-GCACCTGCTCATGGGACAA
*:UK = Unknown.BMC Genomics 2009, 10:424 http://www.biomedcentral.com/1471-2164/10/424
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Survival curves were computed using Kaplan-Meier prod-
uct limit estimator. Hazard ratios for continuous and dis-
crete variables were estimated through Cox's proportional
hazard regression models. A backward stepwise selection
based on likelihood ratio tests was used for the identifica-
tion of the covariates to be kept in the final Cox regression
models.
All p-values were two-tailed and p-values < 0.05 were con-
sidered statistically significant. All statistical analyses were
carried out using R version 2.5.1 and SPSS version 15
(SPSS Inc. 1999, Chicago IL.).
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